Acusense had been selected to join the Caelestinus Health Tech Innovator Program

Acusense began its entry into the European market starting with the Czech Republic in Central and Eastern Europe, marking a new chapter in its international expansion. In April 2023, Acusense was successfully selected to participate in the Caelestinus accelerator program in the Czech Republic, representing a significant step toward entering the European market.

The Caelestinus Accelerator, located in Prague, the capital of the Czech Republic, is an accelerator focused on hybrid digital health interoperability and FHIR (Fast Healthcare Interoperability Resources) technology. This three-month acceleration program is supported by the renowned company InterSystems and backed by major institutions such as IKEM (Institute for Clinical and Experimental Medicine), the largest transplant center in Europe. Participating companies receive mentorship from top professionals in healthcare, technology, law, and marketing, gaining valuable market validation and support.

The Caelestinus Accelerator Program provided Xiang’an Biomedical with a valuable opportunity to further expand into the European market. Through this program, Acusense gained in-depth insights into the needs and dynamics of the European market and established connections with local medical institutions and technology partners. This not only enhanced the company’s international visibility but also laid a solid foundation for its long-term development in Europe. Participation in the accelerator signifies that Xiang’an Biomedical’s technological innovations and market strategies have been recognized and supported by internationally renowned institutions, opening up new possibilities for its future global expansion.